# A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

> **NCT06279364** · PHASE3 · RECRUITING · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 524 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** SKB264
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Capecitabine
- **DRUG:** Eribulin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06279364
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-28
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 524 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279364, "A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT06279364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*